In recent years, immune checkpoint blockade immunotherapy, particularly targeting PD-1/PD-L1, has become a pivotal strategy for treating lung cancer, including non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). This evidence concerns the gene CD274 and small cell lung carcinoma.